{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T10:46:37Z","timestamp":1788432397520,"version":"build-2803163510"},"reference-count":81,"publisher":"BMJ","issue":"3","content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["Pract Neurol"],"accepted":{"date-parts":[[2022,1,16]]},"published-print":{"date-parts":[[2022,6]]},"abstract":"<jats:p>The Optic Neuritis Treatment Trial previously reported that corticosteroids accelerated visual recovery in optic neuritis (ON) without improving outcome. This finding related largely to multiple sclerosis (MS), and subsequently neurologists tended to await spontaneous recovery in ON. Since then, non-MS cases of ON have been identified with antibodies to aquaporin-4 (AQP4) or myelin oligodendrocyte glycoprotein (MOG). These disorders can closely mimic multiple sclerosis-associated or idiopathic demyelinating optic neuritis (MS\/IDON) initially but risk a worse visual outcome. Scrutinising the clinical features and neuroimaging often enables differentiation between MS\/IDON and other causes of ON. Early treatment with high-dose corticosteroids is an important determinant of visual outcome in non-MS\/IDON. Prompt use of plasma exchange may also save sight. In this review, we contrast the presentations of myelin oligodendrocyte glycoprotein associated optic neuritis (MOG-ON) and aquaporin 4 associated optic neuritis (AQP4-ON) with MS\/IDON and provide an approach to acute management while awaiting results of antibody testing.<\/jats:p>","DOI":"10.1136\/practneurol-2021-003228","type":"journal-article","created":{"date-parts":[[2022,5,2]],"date-time":"2022-05-02T13:25:33Z","timestamp":1651497933000},"page":"190-200","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":3,"title":["Optic neuritis with potential for poor outcome"],"prefix":"10.1136","volume":"22","author":[{"given":"Sarah A","family":"Cooper","sequence":"first","affiliation":[{"name":"Neurology, University Hospitals Sussex NHS Foundation Trust, Brighton, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara Geraldine","family":"Leddy","sequence":"additional","affiliation":[{"name":"Neurology, University Hospitals Sussex NHS Foundation Trust, Brighton, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicholas Tom","family":"Skipper","sequence":"additional","affiliation":[{"name":"Neuroradiology, University Hospitals Sussex NHS Foundation Trust, Brighton, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Victoria J M","family":"Barrett","sequence":"additional","affiliation":[{"name":"Ophthalmology, University Hospitals Sussex NHS Foundation Trust, Brighton, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gordon T","family":"Plant","sequence":"additional","affiliation":[{"name":"University College London, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2022,5,2]]},"reference":[{"key":"2025090410310548000_22.3.190.1","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1111\/nyas.12794","article-title":"Neuromyelitis optica and the evolving spectrum of autoimmune aquaporin-4 channelopathies: a decade later","volume":"1366","author":"Pittock","year":"2016","journal-title":"Ann N Y Acad Sci"},{"key":"2025090410310548000_22.3.190.2","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1056\/NEJM199202273260901","article-title":"A randomized, controlled trial of corticosteroids in the treatment of acute optic neuritis","volume":"326","author":"Beck","year":"1992","journal-title":"N Engl J Med Overseas Ed"},{"key":"2025090410310548000_22.3.190.3","doi-asserted-by":"publisher","DOI":"10.1093\/brain\/awg045"},{"key":"2025090410310548000_22.3.190.4","doi-asserted-by":"publisher","DOI":"10.1001\/archopht.1991.01080120057025"},{"key":"2025090410310548000_22.3.190.5","doi-asserted-by":"publisher","DOI":"10.1016\/S0161-6420(94)31103-1"},{"key":"2025090410310548000_22.3.190.6","doi-asserted-by":"publisher","DOI":"10.1038\/nrneurol.2013.98"},{"key":"2025090410310548000_22.3.190.7","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.ajo.2018.07.020","article-title":"Myelin oligodendrocyte glycoprotein antibody-positive optic neuritis: clinical characteristics, radiologic clues, and outcome","volume":"195","author":"Chen","year":"2018","journal-title":"Am J Ophthalmol"},{"key":"2025090410310548000_22.3.190.8","doi-asserted-by":"publisher","DOI":"10.1177\/1352458515593406"},{"key":"2025090410310548000_22.3.190.9","doi-asserted-by":"crossref","DOI":"10.3389\/fneur.2020.00778","article-title":"Pain in NMOSD and MOGAD: a systematic literature review of pathophysiology, symptoms, and current treatment strategies","volume":"11","author":"Asseyer","year":"2020","journal-title":"Front Neurol"},{"key":"2025090410310548000_22.3.190.10","doi-asserted-by":"publisher","DOI":"10.1136\/practneurol-2015-001254"},{"key":"2025090410310548000_22.3.190.11","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1038\/s41433-020-01334-8","article-title":"Neuromyelitis optica spectrum disorder and myelin oligodendrocyte glycoprotein associated disorder-optic neuritis: a comprehensive review of diagnosis and treatment","volume":"35","author":"Gospe","year":"2021","journal-title":"Eye"},{"key":"2025090410310548000_22.3.190.12","doi-asserted-by":"publisher","DOI":"10.1016\/j.preteyeres.2013.03.001"},{"key":"2025090410310548000_22.3.190.13","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000000101"},{"key":"2025090410310548000_22.3.190.14","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(13)70259-X"},{"key":"2025090410310548000_22.3.190.15","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1016\/j.msard.2018.10.003","article-title":"Atypical anti-MOG syndrome with aseptic meningoencephalitis and pseudotumor cerebri-like presentations","volume":"27","author":"Narayan","year":"2019","journal-title":"Mult Scler Relat Disord"},{"key":"2025090410310548000_22.3.190.16","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1016\/j.joco.2019.03.005","article-title":"Update on Bartonella neuroretinitis","volume":"31","author":"Ksiaa","year":"2019","journal-title":"J Curr Ophthalmol"},{"key":"2025090410310548000_22.3.190.17","doi-asserted-by":"crossref","DOI":"10.3389\/fneur.2020.00501","article-title":"Epidemiology of neuromyelitis optica spectrum disorder and its prevalence and incidence worldwide","volume":"11","author":"Hor","year":"2020","journal-title":"Front Neurol"},{"key":"2025090410310548000_22.3.190.18","doi-asserted-by":"crossref","first-page":"S14","DOI":"10.1097\/WNO.0000000000000551","article-title":"Pediatric optic neuritis: what is new","volume":"37 Suppl 1","author":"Borchert","year":"2017","journal-title":"J Neuroophthalmol"},{"key":"2025090410310548000_22.3.190.19","doi-asserted-by":"publisher","DOI":"10.1001\/archneurol.2012.314"},{"key":"2025090410310548000_22.3.190.20","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2020.540156"},{"key":"2025090410310548000_22.3.190.21","doi-asserted-by":"publisher","DOI":"10.1186\/s12974-016-0718-0"},{"key":"2025090410310548000_22.3.190.22","doi-asserted-by":"crossref","first-page":"194","DOI":"10.4103\/ijo.IJO_887_21","article-title":"Clinical profile, imaging features and short term visual outcomes of Indian optic neuritis patients with and without seromarkers for myelin oligodendrocyte glycoprotein and neuromyelitis optica","volume":"70","author":"Ambika","year":"2022","journal-title":"Indian J Ophthalmol"},{"key":"2025090410310548000_22.3.190.23","doi-asserted-by":"crossref","first-page":"1127","DOI":"10.1136\/jnnp-2020-323158","article-title":"Prevalence and incidence of NMOSD, AQP4-antibody positive NMOSD and MOG-antibody positive disease in Oxfordshire, UK","volume":"91","author":"Connell K","year":"2020","journal-title":"J Neuro Neurosurg Psychiatr"},{"key":"2025090410310548000_22.3.190.24","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp-2019-320493"},{"key":"2025090410310548000_22.3.190.25","doi-asserted-by":"publisher","DOI":"10.1212\/NXI.0000000000000270"},{"key":"2025090410310548000_22.3.190.26","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp-2016-314005"},{"key":"2025090410310548000_22.3.190.27","doi-asserted-by":"publisher","DOI":"10.1093\/brain\/awf087"},{"key":"2025090410310548000_22.3.190.28","doi-asserted-by":"publisher","DOI":"10.1016\/j.jns.2015.05.013"},{"key":"2025090410310548000_22.3.190.29","doi-asserted-by":"publisher","DOI":"10.1097\/WNO.0b013e318254c62d"},{"key":"2025090410310548000_22.3.190.30","first-page":"205521731879119","article-title":"Differences in clinical features between optic neuritis in neuromyelitis optica spectrum disorders and in multiple sclerosis","volume":"4","author":"Srikajon","year":"2018","journal-title":"Mult Scler J Exp Transl Clin"},{"key":"2025090410310548000_22.3.190.31","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1177\/13524585211011450","article-title":"Optic chiasm involvement in AQP-4 antibody-positive NMO and MOG antibody-associated disorder","volume":"28","author":"Tajfirouz","year":"2022","journal-title":"Mult Scler"},{"key":"2025090410310548000_22.3.190.32","doi-asserted-by":"publisher","DOI":"10.1212\/NXI.0000000000000163"},{"key":"2025090410310548000_22.3.190.33","doi-asserted-by":"crossref","DOI":"10.3389\/fneur.2020.627077","article-title":"Optic perineuritis and its association with autoimmune diseases","volume":"11","author":"Li","year":"2020","journal-title":"Front Neurol"},{"key":"2025090410310548000_22.3.190.34","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp.74.11.1577"},{"key":"2025090410310548000_22.3.190.35","doi-asserted-by":"publisher","DOI":"10.1093\/brain\/awz144"},{"key":"2025090410310548000_22.3.190.36","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(17)30470-2"},{"key":"2025090410310548000_22.3.190.37","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.2214\/AJR.20.24061","article-title":"MOGAD: how it differs from and resembles other neuroinflammatory disorders","volume":"216","author":"Shahriari","year":"2021","journal-title":"AJR Am J Roentgenol"},{"key":"2025090410310548000_22.3.190.38","doi-asserted-by":"publisher","DOI":"10.1016\/j.msard.2019.01.021"},{"key":"2025090410310548000_22.3.190.39","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1093\/brain\/aww350","article-title":"Distinct brain imaging characteristics of autoantibody-mediated CNS conditions and multiple sclerosis","volume":"140","author":"Jurynczyk","year":"2017","journal-title":"Brain"},{"key":"2025090410310548000_22.3.190.40","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000001367"},{"key":"2025090410310548000_22.3.190.41","doi-asserted-by":"publisher","DOI":"10.1001\/archneur.63.7.964"},{"key":"2025090410310548000_22.3.190.42","doi-asserted-by":"publisher","DOI":"10.1001\/archneur.63.3.390"},{"key":"2025090410310548000_22.3.190.43","doi-asserted-by":"publisher","DOI":"10.1212\/01.wnl.0000216139.44259.74"},{"key":"2025090410310548000_22.3.190.44","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1001\/jamaneurol.2018.4053","article-title":"Clinical, radiologic, and prognostic features of myelitis associated with myelin oligodendrocyte glycoprotein autoantibody","volume":"76","author":"Dubey","year":"2019","journal-title":"JAMA Neurol"},{"key":"2025090410310548000_22.3.190.45","doi-asserted-by":"publisher","DOI":"10.3174\/ajnr.A5551"},{"key":"2025090410310548000_22.3.190.46","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2021.37833","article-title":"Frequency of new silent MRI lesions in MOG-antibody disease and AQP4-antibody neuromyelitis optica spectrum disorder","volume":"4","author":"Camera","year":"2021","journal-title":"JAMA Netw Open"},{"key":"2025090410310548000_22.3.190.47","doi-asserted-by":"crossref","first-page":"3857","DOI":"10.3390\/jcm9123857","article-title":"Factors associated with changes in retina layers following acute optic neuritis: a longitudinal study using optical coherence tomography","volume":"9","author":"Lim","year":"2020","journal-title":"J Clin Med"},{"key":"2025090410310548000_22.3.190.48","doi-asserted-by":"crossref","first-page":"1064","DOI":"10.1038\/eye.2011.125","article-title":"Macular findings on optical coherence tomography in cat-scratch disease neuroretinitis","volume":"25","author":"Habot-Wilner","year":"2011","journal-title":"Eye"},{"key":"2025090410310548000_22.3.190.49","doi-asserted-by":"publisher","DOI":"10.1177\/1352458514567216"},{"key":"2025090410310548000_22.3.190.50","doi-asserted-by":"publisher","DOI":"10.1111\/j.1468-1331.2010.03066.x"},{"key":"2025090410310548000_22.3.190.51","doi-asserted-by":"publisher","DOI":"10.1136\/practneurol-2017-001787"},{"key":"2025090410310548000_22.3.190.52","doi-asserted-by":"publisher","DOI":"10.1093\/brain\/awu335"},{"key":"2025090410310548000_22.3.190.53","doi-asserted-by":"crossref","first-page":"3128","DOI":"10.1093\/brain\/awx276","article-title":"Clinical presentation and prognosis in MOG-antibody disease: a UK study","volume":"140","author":"Jurynczyk","year":"2017","journal-title":"Brain"},{"key":"2025090410310548000_22.3.190.54","doi-asserted-by":"publisher","DOI":"10.1212\/NXI.0000000000000572"},{"key":"2025090410310548000_22.3.190.55","doi-asserted-by":"publisher","DOI":"10.1007\/s00417-010-1344-7"},{"key":"2025090410310548000_22.3.190.56","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1155\/2011\/815068","article-title":"Hyperacute corticosteroid treatment of optic neuritis at the onset of pain may prevent visual loss: a case series","volume":"2011","author":"Plant","year":"2011","journal-title":"Mult Scler Int"},{"key":"2025090410310548000_22.3.190.57","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.brainres.2017.08.012","article-title":"Time is vision in recurrent optic neuritis","volume":"1673","author":"Osinga","year":"2017","journal-title":"Brain Res"},{"key":"2025090410310548000_22.3.190.58","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp-2019-321653"},{"key":"2025090410310548000_22.3.190.59","doi-asserted-by":"crossref","first-page":"1479","DOI":"10.1212\/WNL.52.7.1479","article-title":"A randomized, controlled trial of oral high-dose methylprednisolone in acute optic neuritis","volume":"52","author":"Sellebjerg","year":"1999","journal-title":"Neurology"},{"key":"2025090410310548000_22.3.190.60","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1001\/jamaneurol.2018.0024","article-title":"Effect of treating acute optic neuritis with bioequivalent oral vs intravenous corticosteroids","volume":"75","author":"Morrow","year":"2018","journal-title":"JAMA Neurol"},{"key":"2025090410310548000_22.3.190.61","doi-asserted-by":"publisher","DOI":"10.1016\/S0002-9394(03)00862-6"},{"key":"2025090410310548000_22.3.190.62","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp-2017-316880"},{"key":"2025090410310548000_22.3.190.63","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1046\/j.1537-2995.1999.39070671.x","article-title":"Selective therapeutic extraction of plasma constituents, revisited","volume":"39","author":"Pineda","year":"1999","journal-title":"Transfusion"},{"key":"2025090410310548000_22.3.190.64","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1002\/art.1780240901","article-title":"Therapeutic plasmapheresis in systemic lupus erythematosus. Effect on immune complexes and antibodies to DNA","volume":"24","author":"Jones","year":"1981","journal-title":"Arthritis Rheum"},{"key":"2025090410310548000_22.3.190.65","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1159\/000008227","article-title":"Lymphocyte subset proportions in Guillain-Barr\u00e9 syndrome patients treated with plasmapheresis","volume":"44","author":"Yoshii","year":"2000","journal-title":"Eur Neurol"},{"key":"2025090410310548000_22.3.190.66","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1155\/2012\/787630","article-title":"Plasma exchange in severe attacks of neuromyelitis optica","volume":"2012","author":"Bonnan","year":"2012","journal-title":"Mult Scler Int"},{"key":"2025090410310548000_22.3.190.67","doi-asserted-by":"publisher","DOI":"10.1002\/ana.24554"},{"key":"2025090410310548000_22.3.190.68","doi-asserted-by":"crossref","first-page":"4549","DOI":"10.1007\/s00415-020-10257-z","article-title":"Therapeutic plasma exchange vs conventional treatment with intravenous high dose steroid for neuromyelitis optica spectrum disorders (NMOSD): a systematic review and meta-analysis","volume":"268","author":"Siritho","year":"2021","journal-title":"J Neurol"},{"key":"2025090410310548000_22.3.190.69","doi-asserted-by":"publisher","DOI":"10.1007\/s00415-013-7169-7"},{"key":"2025090410310548000_22.3.190.70","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp-2017-316286"},{"key":"2025090410310548000_22.3.190.71","first-page":"205521731562279","article-title":"Improvement to baseline after plasma exchange in spinal attacks associated with neuromyelitis optica","volume":"1","author":"Bonnan","year":"2015","journal-title":"Mult Scler J Exp Transl Clin"},{"key":"2025090410310548000_22.3.190.72","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0134583","article-title":"Response to therapeutic plasma exchange as a rescue treatment in clinically isolated syndromes and acute worsening of multiple sclerosis: a retrospective analysis of 90 patients","volume":"10","author":"Ehler","year":"2015","journal-title":"PLoS One"},{"key":"2025090410310548000_22.3.190.73","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(05)67102-4"},{"key":"2025090410310548000_22.3.190.74","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2020.102109","article-title":"Beneficial effects of intravenous immunoglobulin as an add-on therapy to azathioprine for NMO-IgG-seropositive neuromyelitis optica spectrum disorders","volume":"42","author":"Lim","year":"2020","journal-title":"Mult Scler Relat Disord"},{"key":"2025090410310548000_22.3.190.75","first-page":"10325","article-title":"Intravenous immunoglobulin for acute attacks in NMOSD","volume":"44","author":"Li","year":"2020","journal-title":"Mult Scler Rel Dis"},{"key":"2025090410310548000_22.3.190.76","doi-asserted-by":"crossref","first-page":"e1642","DOI":"10.1212\/WNL.0000000000006392","article-title":"Area postrema syndrome: frequency, criteria, and severity in AQP4-IgG-positive NMOSD","volume":"91","author":"Shosha","year":"2018","journal-title":"Neurology"},{"key":"2025090410310548000_22.3.190.77","doi-asserted-by":"publisher","DOI":"10.1038\/nrneurol.2010.147"},{"key":"2025090410310548000_22.3.190.78","doi-asserted-by":"crossref","first-page":"1267","DOI":"10.1002\/art.41709","article-title":"Epidemiology of scleritis in the United Kingdom from 1997 to 2018: population-based analysis of 11 million patients and association between scleritis and infectious and immune-mediated inflammatory disease","volume":"73","author":"Braithwaite","year":"2021","journal-title":"Arthritis Rheumatol"},{"key":"2025090410310548000_22.3.190.79","doi-asserted-by":"publisher","DOI":"10.1016\/j.jns.2011.03.038"},{"key":"2025090410310548000_22.3.190.80","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2019.00726","article-title":"The cerebrospinal fluid in multiple sclerosis","volume":"10","author":"Deisenhammer","year":"2019","journal-title":"Front Immunol"},{"key":"2025090410310548000_22.3.190.81","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp-2019-322286"}],"container-title":["Practical Neurology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/practneurol-2021-003228","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,4]],"date-time":"2025-09-04T17:31:21Z","timestamp":1757007081000},"score":1,"resource":{"primary":{"URL":"https:\/\/pn.bmj.com\/lookup\/doi\/10.1136\/practneurol-2021-003228"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,5,2]]},"references-count":81,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2022,5,17]]},"published-print":{"date-parts":[[2022,6]]}},"alternative-id":["10.1136\/practneurol-2021-003228"],"URL":"https:\/\/doi.org\/10.1136\/practneurol-2021-003228","relation":{},"ISSN":["1474-7758","1474-7766"],"issn-type":[{"value":"1474-7758","type":"print"},{"value":"1474-7766","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,5,2]]}}}